JP2008538923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538923A5 JP2008538923A5 JP2008509012A JP2008509012A JP2008538923A5 JP 2008538923 A5 JP2008538923 A5 JP 2008538923A5 JP 2008509012 A JP2008509012 A JP 2008509012A JP 2008509012 A JP2008509012 A JP 2008509012A JP 2008538923 A5 JP2008538923 A5 JP 2008538923A5
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide riboside
- seq
- nucleotide sequence
- cell
- nicotinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 16
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 16
- 239000011618 nicotinamide riboside Substances 0.000 claims 16
- 108010021066 nicotinamide riboside kinase Proteins 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108030003379 NAD(+) synthases Proteins 0.000 claims 2
- -1 Nicotine riboside Chemical class 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/113,701 US20050227327A1 (en) | 2004-02-10 | 2005-04-25 | Nicotinamide riboside kinase compositions and methods for using the same |
| PCT/US2006/015495 WO2006116322A2 (en) | 2005-04-25 | 2006-04-20 | Nicotinamide riboside kinase compositions and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538923A JP2008538923A (ja) | 2008-11-13 |
| JP2008538923A5 true JP2008538923A5 (https=) | 2009-03-19 |
Family
ID=37215374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509012A Pending JP2008538923A (ja) | 2005-04-25 | 2006-04-20 | ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050227327A1 (https=) |
| EP (1) | EP1877068A4 (https=) |
| JP (1) | JP2008538923A (https=) |
| AU (1) | AU2006238858B2 (https=) |
| CA (1) | CA2609633C (https=) |
| WO (1) | WO2006116322A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US20100047177A1 (en) * | 2007-01-26 | 2010-02-25 | Washington University | Methods and compositions for treating neuropathies |
| KR101186130B1 (ko) | 2010-08-10 | 2012-09-27 | (주)다미화학 | 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물 |
| CA2951287A1 (en) | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
| WO2017004101A1 (en) * | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Skin care compositions comprising particles with nicotinamide riboside and methods of using the same |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| US20160374918A1 (en) * | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Encapsulated skin care agent |
| KR102114892B1 (ko) | 2016-01-11 | 2020-05-26 | 더 프록터 앤드 갬블 캄파니 | 피부 상태의 치료 방법 및 그를 위한 조성물 |
| CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| CN106755209B (zh) * | 2016-12-29 | 2021-07-23 | 苏州汉酶生物技术有限公司 | 一种酶法制备β-烟酰胺单核苷酸的方法 |
| WO2018237218A1 (en) | 2017-06-23 | 2018-12-27 | The Procter & Gamble Company | COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE |
| WO2019108873A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating multiple sclerosis |
| KR20210011964A (ko) | 2018-07-03 | 2021-02-02 | 더 프록터 앤드 갬블 캄파니 | 피부 병태를 치료하는 방법 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| CN115843238B (zh) | 2020-06-01 | 2025-06-10 | 宝洁公司 | 改善维生素b3化合物渗透到皮肤中的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1228222A2 (en) * | 1999-11-04 | 2002-08-07 | Incyte Genomics, Inc. | Human transferase molecules |
| EP1723227A4 (en) * | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
-
2005
- 2005-04-25 US US11/113,701 patent/US20050227327A1/en not_active Abandoned
-
2006
- 2006-04-20 WO PCT/US2006/015495 patent/WO2006116322A2/en not_active Ceased
- 2006-04-20 AU AU2006238858A patent/AU2006238858B2/en not_active Ceased
- 2006-04-20 CA CA2609633A patent/CA2609633C/en not_active Expired - Lifetime
- 2006-04-20 EP EP06751269A patent/EP1877068A4/en not_active Withdrawn
- 2006-04-20 JP JP2008509012A patent/JP2008538923A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538923A5 (https=) | ||
| KR102061353B1 (ko) | 인간 ezh2의 억제제 및 이의 사용 방법 | |
| Gray et al. | Control of translation initiation in animals | |
| Hazra et al. | Oxidative DNA damage repair in mammalian cells: a new perspective | |
| CN105324483B (zh) | 工程化苯丙氨酸解氨酶多肽 | |
| Peng et al. | Mitochondrial E3 ubiquitin ligase 1: A key enzyme in regulation of mitochondrial dynamics and functions | |
| Spry et al. | Coenzyme A biosynthesis: an antimicrobial drug target | |
| Pires et al. | Role of RAD51AP1 in homologous recombination DNA repair and carcinogenesis | |
| Kotsinas et al. | PIG3: a novel link between oxidative stress and DNA damage response in cancer | |
| TWI716841B (zh) | 新穎啟動子及使用該啟動子製造l-胺基酸的方法 | |
| CA2598893A1 (en) | Eml4-alk fusion gene | |
| Lei et al. | N6-methyladenosine (m6A) modification of ribosomal RNAs (rRNAs): Critical roles in mRNA translation and diseases | |
| Vorwerk et al. | A transferable plasticity region in C ampylobacter coli allows isolates of an otherwise non‐glycolytic food‐borne pathogen to catabolize glucose | |
| CN114450392A (zh) | 工程化为体内产生血清素的先进微生物组疗法 | |
| Chang et al. | Differences between Cryptococcus neoformans and Cryptococcus gattii in the molecular mechanisms governing utilization of D-amino acids as the sole nitrogen source | |
| AU2019340845B2 (en) | Method for producing an antitumoral arenavirus as well as arenavirus mutants | |
| CN117730143A (zh) | 通过缀合的n-末端甘氨酸修饰的细胞及其用途 | |
| Amodeo et al. | Diet suppresses glioblastoma initiation in mice by maintaining quiescence of mutation-bearing neural stem cells | |
| JP2022001048A (ja) | B型肝炎治療用組成物、及びb型肝炎ウイルスの複製活性の評価方法 | |
| JP2015502137A (ja) | E1酵素変異体およびその用途 | |
| CN110538179B (zh) | Yg1702在制备aldh18a1特异性抑制剂中的应用 | |
| KR20180095093A (ko) | 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도 | |
| Nicoloff et al. | Repression of the pyr operon in Lactobacillus plantarum prevents its ability to grow at low carbon dioxide levels | |
| Jiang et al. | KDM4 demethylases: structure, function, and inhibitors | |
| Lee et al. | Down syndrome candidate region-1 protein interacts with Tollip and positively modulates interleukin-1 receptor-mediated signaling |